Accelerating optimal approval of priority formulations for antibiotic use in children PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Accelerating optimal approval of priority formulations for antibiotic use in children PDF full book. Access full book title Accelerating optimal approval of priority formulations for antibiotic use in children by World Health Organization. Download full books in PDF and EPUB format.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 924010335X
Category : Medical
Languages : en
Pages : 27
Get Book Here
Book Description
On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments for infants and children. This list, developed through WHO’s Paediatric Drug Optimization (PADO) process, identifies antibiotics urgently needing development to treat infections from high-priority pathogens. WHO, leveraging GAP-f and partners like GARDP and PENTA, led a technical consultation that concluded in March 2024 to review regulatory frameworks and streamline clinical research, aiming to accelerate regulatory approvals and ensure equitable access to effective treatments. The outcomes of this meeting are captured in this report, underscoring the collaborative efforts needed to advance essential paediatric formulations, minimize delays, and support globally aligned, evidence-based care for serious infections in children.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 924010335X
Category : Medical
Languages : en
Pages : 27
Get Book Here
Book Description
On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments for infants and children. This list, developed through WHO’s Paediatric Drug Optimization (PADO) process, identifies antibiotics urgently needing development to treat infections from high-priority pathogens. WHO, leveraging GAP-f and partners like GARDP and PENTA, led a technical consultation that concluded in March 2024 to review regulatory frameworks and streamline clinical research, aiming to accelerate regulatory approvals and ensure equitable access to effective treatments. The outcomes of this meeting are captured in this report, underscoring the collaborative efforts needed to advance essential paediatric formulations, minimize delays, and support globally aligned, evidence-based care for serious infections in children.
Author: Jun Lin
Publisher: Frontiers Media SA
ISBN: 2889195260
Category : Antibiotics
Languages : en
Pages : 226
Get Book Here
Book Description
Antibiotics represent one of the most successful forms of therapy in medicine. But the efficiency of antibiotics is compromised by the growing number of antibiotic-resistant pathogens. Antibiotic resistance, which is implicated in elevated morbidity and mortality rates as well as in the increased treatment costs, is considered to be one of the major global public health threats (www.who.int/drugresistance/en/) and the magnitude of the problem recently prompted a number of international and national bodies to take actions to protect the public (http://ec.europa.eu/dgs/health_consumer/docs/road-map-amr_en.pdf: http://www.who.int/drugresistance/amr_global_action_plan/en/; http://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf). Understanding the mechanisms by which bacteria successfully defend themselves against the antibiotic assault represent the main theme of this eBook published as a Research Topic in Frontiers in Microbiology, section of Antimicrobials, Resistance, and Chemotherapy. The articles in the eBook update the reader on various aspects and mechanisms of antibiotic resistance. A better understanding of these mechanisms should facilitate the development of means to potentiate the efficacy and increase the lifespan of antibiotics while minimizing the emergence of antibiotic resistance among pathogens.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240084592
Category : Business & Economics
Languages : en
Pages : 8
Get Book Here
Book Description
In November-December 2022, WHO undertook a Paediatric Drug Optimization (PADO) exercise for antibiotics, to: identify antibiotics with an approved indication for children for which age-appropriate formulations are missing that need to be given priority for development (PADO priority list); and pipeline or approved antibiotics without an indication for children to be given priority for further investigation and development for children (PADO watch list). Cefiderocol was included in the PADO priority list considering its efficacy against multiple pathogens in the WHO Bacterial Priority Pathogens List, its favorable resistance and cross-resistance profile and considering that clinical trials involving children are ongoing. This information note aims to provide a summary of cefiderocol’s characteristics (regulatory approvals, current formulations, inclusion in the WHO EML etc), current and planned paediatric studies (including neonates) and initiatives to ensure prompt access for all people in need, as well as lay out interventions that should be prioritized by researchers and funders for cefiderocol development, as well as, more broadly for antibiotics that are much needed in children.
Author: National Academies Of Sciences Engineeri
Publisher: National Academies Press
ISBN: 9780309269452
Category : Medical
Languages : en
Pages :
Get Book Here
Book Description
The National Strategy for Combating Antibiotic Resistant Bacteria, published in 2014, sets out a plan for government work to mitigate the emergence and spread of resistant bacteria. Direction on the implementation of this strategy is provided in five-year national action plans, the first covering 2015 to 2020, and the second covering 2020 to 2025. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine evaluates progress made against the national strategy. This report discusses ways to improve detection of resistant infections and estimate the risk to human health from environmental sources of resistance. In addition, the report considers the effect of agricultural practices on human and animal health and animal welfare and ways these practices could be improved, and advises on key drugs and diseases for which animal-specific test breakpoints are needed.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309085438
Category : Medical
Languages : en
Pages : 160
Get Book Here
Book Description
A new release in the Quality Chasm Series, Priority Areas for National Action recommends a set of 20 priority areas that the U.S. Department of Health and Human Services and other groups in the public and private sectors should focus on to improve the quality of health care delivered to all Americans. The priority areas selected represent the entire spectrum of health care from preventive care to end of life care. They also touch on all age groups, health care settings and health care providers. Collective action in these areas could help transform the entire health care system. In addition, the report identifies criteria and delineates a process that DHHS may adopt to determine future priority areas.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 924004812X
Category : Medical
Languages : en
Pages : 72
Get Book Here
Book Description
Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240009582
Category : Medical
Languages : en
Pages : 54
Get Book Here
Book Description
The purpose of the guideline was to provide an evidence-informed recommendation on whether mass drug administration of azithromycin, as a public health intervention for the reduction of under-five mortality, should (a) be rolled out universally in low- and middle-income countries, (b) be applied only in some situational contexts in low-and middle-income countries or (c) not be used at all.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9241548371
Category : Business & Economics
Languages : en
Pages : 442
Get Book Here
Book Description
The Pocket Book is for use by doctors nurses and other health workers who are responsible for the care of young children at the first level referral hospitals. This second edition is based on evidence from several WHO updated and published clinical guidelines. It is for use in both inpatient and outpatient care in small hospitals with basic laboratory facilities and essential medicines. In some settings these guidelines can be used in any facilities where sick children are admitted for inpatient care. The Pocket Book is one of a series of documents and tools that support the Integrated Managem.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9241563435
Category : Medical
Languages : en
Pages : 65
Get Book Here
Book Description
Monitoring the safety of medicine use in children is of paramount importance since during the clinical development of medicines only limited data on this aspect are generated through clinical trials. Use of medicines outside the specifications described in the license (e.g. in terms of formulation indications contraindications or age) constitutes off-label and off-license use and these are a major area of concern. These guidelines are intended to improve awareness of medicine safety issues among everyone who has an interest in the safety of medicines in children and to provide guidance on effective systems for monitoring medicine safety in pediatric populations. This book will be of interest to all health care professionals medicine regulatory authorities pharmacovigilance centres academia the pharmaceutical industry and policy-makers. Systems for monitoring medicine safety are described in Annex 1. Pharmacovigilance methods and some examples of recent information on adverse reactions to marketed medicines are discussed in Annex 2.
Author: Sarfaraz K. Niazi
Publisher: CRC Press
ISBN: 1420048457
Category : Medical
Languages : en
Pages : 258
Get Book Here
Book Description
The third volume in the six-volume Handbook of Pharmaceutical Manufacturing Formulations, this book covers liquid drugs, which include formulations of non-sterile drugs administered by any route in the form of solutions (monomeric and multimeric), suspensions (powder and liquid), drops, extracts, elixirs, tinctures, paints, sprays, colloidons, emul
